Article Information
History
- September 29, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Alexia Lopresti*,1,
- Laurys Boudin*,1,
- Pascal Finetti1,
- Séverine Garnier1,
- Anaïs Aulas1,
- Maria-Lucia Liberatoscioli1,
- Arnaud Guille1,
- Quentin Dacosta1,
- Olivier Cabaud1,
- Jihane Pakradouni2,
- Anthony Goncalves3,
- Daniel Birnbaum1,
- François Bertucci*,1,3,
- Emilie Mamessier*,1,† and
- Claire Acquaviva*,1
- 1CRCM, Predictive Oncology Team, INSERM, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, Marseille, France
- 2Department of Clinical Research and Innovation, Sponsor Unit, Institut Paoli-Calmettes, Mar-seille, France
- 3Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
- ↵†Correspondence to: Mamessier Emilie, emilie.mamessier{at}inserm.fr, +33 486 977 261, 13273 Marseille
↵* These authors equally contribute to the work.
Posted September 29, 2020.
Fine analysis of atypical circulating tumor cells in metastatic breast cancer patients reveals subsets with different prognostic values
